The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban

Young Hoon Kim, Jaemin Shim, Chia Ti Tsai, Chun Chieh Wang, Gilbert Vilela, Sombat Muengtaweepongsa, Mohammad Kurniawan, Oteh Maskon, Li Fern Hsu, Thang Huy Nguyen, Kenneth Sim, A. John Camm

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)1309-1311
Number of pages3
JournalChest
Volume155
Issue number6
DOIs
Publication statusPublished - 2019 Jun 1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Y. H., Shim, J., Tsai, C. T., Wang, C. C., Vilela, G., Muengtaweepongsa, S., Kurniawan, M., Maskon, O., Hsu, L. F., Nguyen, T. H., Sim, K., & Camm, A. J. (2019). The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban. Chest, 155(6), 1309-1311. https://doi.org/10.1016/j.chest.2019.03.036